MAP3K14 and COVID-19: For the STEMI subgroup of patients, we observed significantly higher values of cardiac biomarkers in the COVID-19 group, especially hs troponin I, respectively, 10,327 (941.4, 40,000) vs. 838.8 (140.4, 13,682), p = 0.01, and NT-pro-BNP 5031 (736, 13,341) vs. 193 (81, 2542), p < 0.01 (Table 5).